Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2010 1
2012 1
2013 2
2015 1
2019 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer.
Azim HA, Loutfy SA, Azim HA Jr, Kamal NS, Abdel Fattah NF, Elberry MH, Abdelaziz MR, Abdelsalam M, Aziz M, Shohdy KS, Kassem L. Azim HA, et al. Among authors: kamal ns. Oncol Ther. 2023 Dec;11(4):445-459. doi: 10.1007/s40487-023-00240-9. Epub 2023 Sep 20. Oncol Ther. 2023. PMID: 37731153 Free PMC article. Review.
BACKGROUND: Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In many developing countries, including Egypt, the prevalence of BRCA1/2 mutations among women with breast cancer (BC) is unknown. AIM: …
BACKGROUND: Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In …
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin.
Abdel Azim H, Kassem L, Shohdy KS, Eshaak B, Anis SE, Kamal NS. Abdel Azim H, et al. Among authors: kamal ns. J Breast Cancer. 2019 Mar;22(1):141-148. doi: 10.4048/jbc.2019.22.e2. J Breast Cancer. 2019. PMID: 30941241 Free PMC article.
The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with …
The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patien …
Exploring the safety of chemotherapy for treating breast cancer during pregnancy.
Lambertini M, Kamal NS, Peccatori FA, Del Mastro L, Azim HA Jr. Lambertini M, et al. Among authors: kamal ns. Expert Opin Drug Saf. 2015;14(9):1395-408. doi: 10.1517/14740338.2015.1061500. Epub 2015 Jul 3. Expert Opin Drug Saf. 2015. PMID: 26118333 Review.
INTRODUCTION: The diagnosis of breast cancer during pregnancy (BCP) represents a unique challenge to the patient, her family and the treating physician. ...Recently, a growing amount of data suggests the safety of taxanes during pregnancy. Pregnancy in cancer patien …
INTRODUCTION: The diagnosis of breast cancer during pregnancy (BCP) represents a unique challenge to the patient, her family and the …
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
Azim HA, Bahr SA, Kamal NS, Koura MA, Tolba R, Gad HA, Morsy A, Attia HM, Iskander I, Hammad A, Hemed MF, Abdallah MF, Sadek KA, Taha AH. Azim HA, et al. Among authors: kamal ns. Ecancermedicalscience. 2013 Dec 10;7:378. doi: 10.3332/ecancer.2013.378. eCollection 2013. Ecancermedicalscience. 2013. PMID: 24324529 Free PMC article.
Financial difficulties faced either because patients lacked insurance or because of the restricted National Health Service budget in Egypt have resulted in the unavailability of certain modalities of treatment in cancer care and the need to consider more economic yet effic …
Financial difficulties faced either because patients lacked insurance or because of the restricted National Health Service budget in Egypt h …
Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!
Azim HA, Kamal NS, Malak RA. Azim HA, et al. Among authors: kamal ns. J Thorac Dis. 2013 Jun;5 Suppl 1(Suppl 1):S27-35. doi: 10.3978/j.issn.2072-1439.2013.06.04. J Thorac Dis. 2013. PMID: 23819025 Free PMC article.
During the last 2 decades the role of bisphosphonates (BPs) to reduce skeletal-related events from bone metastases in breast cancer has been well defined. Several preclinical studies have strongly suggested that BPs may also provide an anti-cancer effect in early br …
During the last 2 decades the role of bisphosphonates (BPs) to reduce skeletal-related events from bone metastases in breast cancer h …
Bone metastasis in breast cancer: the story of RANK-ligand.
Azim HA, Kamal NS, Azim HA Jr. Azim HA, et al. Among authors: kamal ns. J Egypt Natl Canc Inst. 2012 Sep;24(3):107-14. doi: 10.1016/j.jnci.2012.06.002. Epub 2012 Jul 10. J Egypt Natl Canc Inst. 2012. PMID: 22929916 Free article. Review.
Preclinical models have shown that breast cancer cells can produce parathyroid hormone-related protein (PTHrP), and other osteolytic molecules, which stimulate excessive osteoclastic bone resorption and establishment of osteolytic lesions. ...In this review, we will focus …
Preclinical models have shown that breast cancer cells can produce parathyroid hormone-related protein (PTHrP), and other osteolytic …
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.
Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, Le Chevalier T, Filipits M, Fouret P; International Adjuvant Lung Trial-Bio investigators. Kamal NS, et al. Clin Cancer Res. 2010 Feb 15;16(4):1206-15. doi: 10.1158/1078-0432.CCR-09-2204. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145178
CONCLUSIONS: MSH2 expression is a borderline significant predictor of a long-term benefit from adjuvant cisplatin-based chemotherapy in patients with completely resected lung cancer. MSH2 combined with ERCC1 or P27 may identify patients most likely to benefit durably from …
CONCLUSIONS: MSH2 expression is a borderline significant predictor of a long-term benefit from adjuvant cisplatin-based chemotherapy in pati …